Goldman Sachs Group Inc Assembly Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$1.09 - $1.52 $19,935 - $27,799	-18,289 Reduced 24.9%	55,148 $71,000
Q4 2022 Feb 13, 2023	SELL	$1.09 - $1.52 $19,935 - $27,799	-18,289 Reduced 24.9%	55,148 $71,000
Q3 2022 May 14, 2024	SELL	$1.7 - $2.34 $5,661 - $7,792	-3,330 Reduced 4.34%	73,437 $120,000
Q3 2022 Nov 10, 2022	SELL	$1.7 - $2.34 $5,661 - $7,792	-3,330 Reduced 4.34%	73,437 $0
Q2 2022 May 14, 2024	BUY	$1.35 - $2.29 $103,635 - $175,796	76,767 New	76,767 $161,000

Q2 2022 Aug 15, 2022	SELL	$1.35 - $2.29 $63,456 - $107,641	-47,005 Reduced 37.98%	76,767 $161,000
Q1 2022 May 16, 2022	BUY	$1.46 - $2.45 $99,880 - $167,606	68,411 Added 123.57%	123,772 $255,000
Q4 2021 Feb 14, 2022	SELL	$2.13 - $3.46 $161,892 - $262,980	-76,006 Reduced 57.86%	55,361 $129,000
Q3 2021 Nov 10, 2021	BUY	$3.14 - $3.9 $412,492 - $512,331	131,367 New	131,367 $457,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.